In this Review:
Lean-NAFLD with central visceral obesity
Hepatocellular carcinoma in HCV cirrhotic patients
Inactivation/delisting of liver transplant after DAA
Intensive care futility in organ failure and ESLD
Antiviral effects on long-term outcome of HDV
TAF vs TDF in HBeAg-positive chronic HBV
Sofosbuvir/ledipasvir for acute HCV genotype 1
NVR 3-778 a first-in-class HBV core inhibitor
Emricasan for cirrhosis and MELD scores 11-18
PPI use with ledipasvir/sofosbuvir
Please login below to download this issue (PDF)